Pharmacy Times – February 2012


Drug Interactions: Insights and Observations


Rivaroxaban: A New Oral Anticoagulant


John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD






1. Xarelto. [package insert]. Titusville, NJ; Janssen Pharmaceuticals, Inc, 2011.

2. Kubitza D et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-21.

3. Mueck W eta l. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453-461.

4. Kubitza D et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703-12.